Filing Flows › Nuvation Bio (NUVB) › Q2 2026 › vs Q1 2026
Nuvation Bio (NUVB) Q2 2026 vs Q1 2026 (quarter over quarter)
Nuvation Bio's revenue fell $51.5M (-62%) from $83.2M in Q1 2026 to $31.7M in Q2 2026.
Nuvation Bio, Q2 2026: revenue $31.7M (+556% year over year), operating margin -161.1%, net loss $62.8M, operating cash flow −$43.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $31.7M | $83.2M | −$51.5M | -62% |
| Net loss | $62.8M | −$5.4M | $68.2M | — |
| Costs & expenses | $94.5M | $84.7M | $9.8M | +12% |
| Operating costs | $82.7M | $79.3M | $3.4M | +4% |
| Interest & other, net | $11.8M | −$1.5M | $13.3M | — |
| Research & development | $30.7M | $35.0M | −$4.4M | -13% |
| SG&A | $42.6M | $38.3M | $4.3M | +11% |
| Other operating costs | $9.5M | $6.0M | $3.5M | +58% |
| Operating cash sources | $62.8M | −$5.4M | $68.2M | — |
| Depreciation & amortization | $536K | $536K | $0 | 0% |
| Share-based compensation | $10.5M | $9.0M | $1.4M | +16% |
| Working capital & other | $8.9M | −$9.9M | $18.8M | — |
| Cash used in operations | $43.0M | −$5.1M | $48.0M | — |
| Net loss absorbed | $62.8M | −$5.4M | $68.2M | — |
Questions
How much did Nuvation Bio's revenue grow quarter over quarter in Q2 2026?
Nuvation Bio's revenue fell $51.5M (-62%) from $83.2M in Q1 2026 to $31.7M in Q2 2026.